Terlipressin Improves Renal Function in Hepatorenal Syndrome Patients

NEW YORK (Reuters Health) Mar 27 – The results of a pilot study indicate that in patients with cirrhosis and hepatorenal syndrome treatment with terlipressin (Glypressin) improves renal function and may provide a bridge to liver transplantation, French researchers report.
Dr. Jean Fran ois Cadranel, from Centre Hospitalier Laennec, Creil, and colleagues treated 18 patients with cirrhosis and hepatorenal syndrome, 16 with type 1 hepatorenal syndrome, and two with type 2 hepatorenal syndrome with terlipressin. Patients were given a median of 4 mg/day terlipressin for an average of 7 days. Thirteen patients received terlipressin by intravenous bolus and five by continuous pump.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים